Hanwei Chen1,2, Dexiang Liu1,2, Yuguo Li2,3, Xiang Xu2,3, Jiadi Xu2,3, Nirbhay N Yadav2,3, Shibin Zhou4, Peter C M van Zijl2,3, Guanshu Liu2,3. 1. Department of Radiology, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China. 2. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland. 4. Ludwig Center, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
PURPOSE: Vascular disrupting therapy of cancer has become a promising approach not only to regress tumor growth directly but also to boost the delivery of chemotherapeutics in the tumor. An imaging approach to monitor the changes in tumor vascular permeability, therefore, has important applications for monitoring of vascular disrupting therapies. METHODS: Mice bearing CT26 subcutaneous colon tumors were injected intravenously with 150 kD dextran (Dex150, diameter, d~ 20 nm, 375 mg/kg), tumor necrosis factor-alpha (TNF-α; 1 µg per mouse), or both (n = 3 in each group). The Z-spectra were acquired before and 2 h after the injection, and the chemical exchange saturation transfer (CEST) signals in the tumors as quantified by asymmetric magnetization transfer ratio (MTRasym ) at 1 ppm were compared. RESULTS: The results showed a significantly stronger CEST contrast enhancement at 1 ppm (∆MTRasym = 0.042 ± 0.002) in the TNF-α-treated tumors than those by Dex150 alone (∆MTRasym = 0.000 ± 0.005, P = 0.0229) or TNF-α alone (∆MTRasym = 0.002 ± 0.004, P = 0.0264), indicating that the TNF-α treatment strongly augmented the tumor uptake of 150 kD dextran. The MRI findings were verified by fluorescence imaging and immunofluorescence microscopy. CONCLUSIONS: High molecular weight dextrans can be used as safe and sensitive CEST MRI contrast agents for monitoring tumor response to vascular disrupting therapy and, potentially, for developing dextran-based theranostic drug delivery systems.
PURPOSE: Vascular disrupting therapy of cancer has become a promising approach not only to regress tumor growth directly but also to boost the delivery of chemotherapeutics in the tumor. An imaging approach to monitor the changes in tumor vascular permeability, therefore, has important applications for monitoring of vascular disrupting therapies. METHODS: Mice bearing CT26 subcutaneous colon tumors were injected intravenously with 150 kD dextran (Dex150, diameter, d~ 20 nm, 375 mg/kg), tumor necrosis factor-alpha (TNF-α; 1 µg per mouse), or both (n = 3 in each group). The Z-spectra were acquired before and 2 h after the injection, and the chemical exchange saturation transfer (CEST) signals in the tumors as quantified by asymmetric magnetization transfer ratio (MTRasym ) at 1 ppm were compared. RESULTS: The results showed a significantly stronger CEST contrast enhancement at 1 ppm (∆MTRasym = 0.042 ± 0.002) in the TNF-α-treated tumors than those by Dex150 alone (∆MTRasym = 0.000 ± 0.005, P = 0.0229) or TNF-α alone (∆MTRasym = 0.002 ± 0.004, P = 0.0264), indicating that the TNF-α treatment strongly augmented the tumor uptake of 150 kD dextran. The MRI findings were verified by fluorescence imaging and immunofluorescence microscopy. CONCLUSIONS: High molecular weight dextrans can be used as safe and sensitive CEST MRI contrast agents for monitoring tumor response to vascular disrupting therapy and, potentially, for developing dextran-based theranostic drug delivery systems.
Authors: Moritz Zaiss; Junzhong Xu; Steffen Goerke; Imad S Khan; Robert J Singer; John C Gore; Daniel F Gochberg; Peter Bachert Journal: NMR Biomed Date: 2014-01-03 Impact factor: 4.044
Authors: Zheng Han; Chuheng Chen; Xiang Xu; Renyuan Bai; Verena Staedtke; Jianpan Huang; Kannie W Y Chan; Jiadi Xu; David O Kamson; Zhibo Wen; Linda Knutsson; Peter C M van Zijl; Guanshu Liu Journal: NMR Biomed Date: 2021-11-15 Impact factor: 4.044
Authors: Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason Journal: Molecules Date: 2021-04-27 Impact factor: 4.411
Authors: Mina Kim; Afroditi Eleftheriou; Luca Ravotto; Bruno Weber; Michal Rivlin; Gil Navon; Martina Capozza; Annasofia Anemone; Dario Livio Longo; Silvio Aime; Moritz Zaiss; Kai Herz; Anagha Deshmane; Tobias Lindig; Benjamin Bender; Xavier Golay Journal: MAGMA Date: 2022-01-15 Impact factor: 2.310